See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Natural Disasters
Holi
Social Media
Vladimir Putin
Artificial Intelligence
European Union
Android
Education
Coronavirus
Formula 1
Donald Trump
Stock Markets
Published • loading... • Updated

CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody

  • CStone Pharmaceuticals announced that the first patient has been dosed in a global Phase I trial of CS2009, a trispecific antibody, with no adverse effects reported.
  • The trial aims to evaluate CS2009's effectiveness against various advanced solid tumors, including lung cancer and cervical cancer.
  • CS2009 targets PD-1, VEGFA, and CTLA-4, potentially improving treatment for patients with low or negative PD-L1 expression.
  • Dr. Jason Yang, CStone CEO, stated that this study marks a breakthrough in their clinical development efforts for innovative therapies.
Insights by Ground AI
Does this summary seem wrong?

29 Articles

All
Left
1
Center
4
Right
2
The Salamanca PressThe Salamanca Press
+25 Reposted by 25 other sources

CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody

SUZHOU, China, March 3, 2025 /PRNewswire/ --CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient has been successfully dosed in the global multicenter Phase I…

Read Full Article
Clinical Trials ArenaClinical Trials Arena

CStone doses first subject in trial of CS2009 for advanced solid tumours

CStone Pharmaceuticals has dosed the first subject in the multicentre Phase I trial of its trispecific antibody, CS2009.The post CStone doses first subject in trial of CS2009 for advanced solid tumours appeared first on Clinical Trials Arena.

Read Full Article
pressreach.compressreach.com

CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody - PressReach

SUZHOU, China, March 3, 2025 /PRNewswire/ –CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient has been successfully dosed in the global multicenter Phase I clinical trial of its novel PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, with no infusion reactions or other adverse events observed. This tria…

Read Full Article
pipelinereviewpipelinereview

CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody - Pipelinereview

SUZHOU, China I March 3, 2025 I CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient has been successfully dosed in the global multicenter Phase I clinical trial of its novel PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, with no infusion reactions or other adverse events observed. This trial aims to e…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 57% of the sources are Center
57% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Brattleboro Reformer broke the news in on Tuesday, March 4, 2025.
Sources are mostly out of (0)

Similar News Topics

Suzhou, China

Suzhou, China

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
Search
BlindspotLocal